Immunogenicity of anti-TNF biologic agents in the treatment of rheumatoid arthritis.

@article{Mok2016ImmunogenicityOA,
  title={Immunogenicity of anti-TNF biologic agents in the treatment of rheumatoid arthritis.},
  author={Chi Chiu Mok and Wen Chan Tsai and Der Yuan Chen and James Cheng - Chung Wei},
  journal={Expert opinion on biological therapy},
  year={2016},
  volume={16 2},
  pages={201-11}
}
INTRODUCTION The use of biologic disease-modifying anti-rheumatic drugs (DMARDs), including therapeutic antibodies, antibody fragments and protein constructs that target key mediators in the pathophysiology of rheumatoid arthritis (RA), has improved the chance of achieving low disease activity and clinical remission. However, individual patients respond differently to biologic DMARD therapy, particularly the tumor necrosis factor (TNF) inhibitors. AREAS COVERED While the variation of clinical… CONTINUE READING